Cempra, Inc. (NASDAQ:CEMP) has been assigned an average rating of “Hold” from the twenty research firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $8.85.

CEMP has been the subject of several analyst reports. Jefferies Group LLC restated a “hold” rating and issued a $3.00 target price on shares of Cempra in a research note on Thursday, May 25th. ValuEngine downgraded Cempra from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Zacks Investment Research downgraded Cempra from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. Roth Capital downgraded Cempra from a “buy” rating to a “neutral” rating and cut their target price for the stock from $8.00 to $4.00 in a research note on Thursday, August 10th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $4.00 target price on shares of Cempra in a research note on Thursday, August 10th.

ILLEGAL ACTIVITY WARNING: “Cempra, Inc. (CEMP) Given Average Rating of “Hold” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/16/cempra-inc-cemp-given-average-rating-of-hold-by-analysts.html.

Institutional investors and hedge funds have recently modified their holdings of the company. Bank of Montreal Can boosted its position in shares of Cempra by 187.8% during the 1st quarter. Bank of Montreal Can now owns 113,933 shares of the biotechnology company’s stock valued at $428,000 after acquiring an additional 74,343 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in shares of Cempra by 35.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 6,800 shares during the last quarter. Bogle Investment Management L P DE raised its holdings in shares of Cempra by 607.0% during the 1st quarter. Bogle Investment Management L P DE now owns 709,518 shares of the biotechnology company’s stock valued at $2,660,000 after buying an additional 609,168 shares in the last quarter. Teachers Advisors LLC raised its holdings in shares of Cempra by 5.2% during the 4th quarter. Teachers Advisors LLC now owns 93,481 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 4,632 shares in the last quarter. Finally, South Dakota Investment Council raised its holdings in shares of Cempra by 19.6% during the 1st quarter. South Dakota Investment Council now owns 706,207 shares of the biotechnology company’s stock valued at $2,648,000 after buying an additional 115,707 shares in the last quarter. Hedge funds and other institutional investors own 49.76% of the company’s stock.

Cempra (NASDAQ:CEMP) opened at 3.10 on Friday. The company has a 50-day moving average price of $3.23 and a 200-day moving average price of $3.80. Cempra has a 1-year low of $2.55 and a 1-year high of $26.95. The firm’s market cap is $162.77 million.

Cempra (NASDAQ:CEMP) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $3.58 million. During the same quarter last year, the company earned ($0.51) EPS. The firm’s revenue was down 74.9% compared to the same quarter last year. On average, equities research analysts forecast that Cempra will post ($1.01) EPS for the current fiscal year.

About Cempra

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.